SCHEMBL1753091

SCHEMBL1753091

CCOC(=O)c1c(N)ncn1Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.53
RECQL P46063 1/20 0.53
MAPK10 P53779 1/20 0.53
MAPK1 P28482 1/20 0.52
TSHR P16473 4/20 0.51
GAA P10253 3/20 0.51
PKM P14618 1/20 0.51
ALDH1A1 P00352 7/20 0.48
KDM4E B2RXH2 4/20 0.48
HSD17B10 Q99714 3/20 0.48
RAB9A P51151 3/20 0.48
LMNA P02545 2/20 0.48
TP53 P04637 2/20 0.48
HPGD P15428 2/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
F2RL3 Q96RI0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16028248 0.88 SMN1; SMN2 (0.54) SMN1; SMN2RECQLMAPK10MAPK1GAA
SCHEMBL11213556 0.86 SMN1; SMN2 (0.55) SMN1; SMN2RECQLMAPK10MAPK1TSHR
SCHEMBL843514 0.86 TUBB4A (0.49) SMN1; SMN2RECQLMAPK10MAPK1GAA
SCHEMBL17456271 0.84 SMN1; SMN2 (0.53) SMN1; SMN2RECQLMAPK10MAPK1TSHR
SCHEMBL2700156 0.84 SMN1; SMN2 (0.50) SMN1; SMN2RECQLMAPK10MAPK1TSHR
SCHEMBL28567653 0.82 LMNA (0.45) SMN1; SMN2RECQLMAPK10MAPK1GAA
SCHEMBL1753177 0.82 MAPK1 (0.55) SMN1; SMN2RECQLMAPK10MAPK1TSHR
SCHEMBL5483136 0.80 PKM (0.59) TSHRGAAPKMALDH1A1LMNA
SCHEMBL17456331 0.79 SMN1; SMN2 (0.48) SMN1; SMN2RECQLMAPK10MAPK1TSHR
Hydrochloric Acid SCHEMBL7987445 0.79 PKM (0.57) TSHRGAAPKMALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722691-B2 Azolopyrimidines as inhibitors of cannabinoid 1 activity IRM LLC (BM) 2014-05-13 US disclosed
US-8722691-B2 Azolopyrimidines as inhibitors of cannabinoid 1 activity IRM LLC (BM) 2014-05-13 US disclosed
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2012-09-06 US disclosed
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2012-09-06 US disclosed
EP-2194046-B1 Triazolone derivative EISAI R&D MAN CO LTD (JP) 2012-05-09 EP disclosed
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 US disclosed
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 US disclosed
US-7816522-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2010-10-19 US disclosed
EP-2194046-A1 Triazolone derivative Eisai R&D Management Co., Ltd. (JP) 2010-06-09 EP disclosed
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity IRM LLC (BM) 2009-10-01 US disclosed
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity IRM LLC (BM) 2009-10-01 US disclosed
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2009-10-01 US disclosed
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2009-10-01 US disclosed
EP-2000465-A1 TRIAZOLONE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-12-10 EP disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed
WO-2003042216-A1 POLYCYCLIC GUANINE DERIVATIVE PHOSPHODIESTERASE V INHIBITORS SCHERING CORPORATION (US) 2003-05-22 WO disclosed
WO-2003020724-A1 POLYCYCLIC GUANINE PHOSPHODIESTERASE V INHIBITORS SCHERING CORPORATION (US) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247556-A1 Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity CNR1, CNR2, ITPR2 SMN1; SMN2 4375/4885RECQL 3532/4885MAPK10 2074/4885
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH SMN1; SMN2 3746/4885RECQL 4664/4885MAPK10 1271/4885
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH SMN1; SMN2 3746/4885RECQL 4664/4885MAPK10 1271/4885
US-20080015199-A1 Triazolone derivatives F3, F12, F2 SMN1; SMN2 3935/4885RECQL 742/4885MAPK10 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.